Carfilzomib: Phase Ib/II data

The open-label, U.S. Phase Ib/II PX-171-007 trial in 24 patients with relapsed and/or refractory MM showed that twice-weekly 56 mg/m 2 carfilzomib given as a 30-minute infusion for 3 weeks of a 4-week cycle plus dexamethasone produced an ORR of 60%, including 1 stringent complete response, 4 very good partial responses and 7 partial responses. Additionally, 1 minor response and 4 cases of stable disease were reported. The most common >=grade 3 adverse events were thrombocytopenia, anemia and hypertension. Data were presented at the American Society of Hematology meeting in San Diego. ...